Checkpoint inhibitors, chemotherapy, and biologics have advanced cancer treatment, yet poor penetration of the tumor microenvironment (TME) and rapidly developing resistance remain major obstacles. Ample preclinical and clinical data from years of research indicate that angiotensin receptor blockers (ARBs), widely used for hypertension, may improve cancer therapy outcomes by modifying the TME. However, to date, no approach has successfully enabled systemic ARB administration without causing dangerous blood pressure–lowering effects.

Pioneering work by Prof. Chezy Barenholz and his team at the Hebrew University of Jerusalem demonstrated that nano-liposome-encapsulated candesartan can modulate the immune response within tumors and enhance the effectiveness of cancer therapies while maintaining normal blood pressure. Their targeted delivery approach is expected to enhance drug accumulation in tumors through the enhanced permeability and retention (EPR) effect and is anticipated to significantly improve the efficacy and safety of a broad range of oncology therapies while minimizing systemic side effects.

Translating these findings into therapeutic development, Revium Rx is advancing liposomal nano-candesartan as a tumor-targeted adjuvant to oncology treatments, focusing on addressing critical needs in patient populations with limited or no effective treatment options.

Checkpoint inhibitors, chemotherapy, and biologics have advanced cancer treatment, yet poor penetration of the tumor microenvironment (TME) and rapidly developing resistance remain major obstacles. Ample preclinical and clinical data from years of research indicate that angiotensin receptor blockers (ARBs), widely used for hypertension, may improve cancer therapy outcomes by modifying the TME. However, to date, no approach has successfully enabled systemic ARB administration without causing dangerous blood pressure–lowering effects.

Pioneering work by Prof. Chezy Barenholz and his team at the Hebrew University of Jerusalem demonstrated that nano-liposome-encapsulated candesartan can modulate the immune response within tumors and enhance the effectiveness of cancer therapies while maintaining normal blood pressure. Their targeted delivery approach is expected to enhance drug accumulation in tumors through the enhanced permeability and retention (EPR) effect and is anticipated to significantly improve the efficacy and safety of a broad range of oncology therapies while minimizing systemic side effects.

Translating these findings into therapeutic development, Revium Rx is advancing liposomal nano-candesartan as a tumor-targeted adjuvant to oncology treatments, focusing on addressing critical needs in patient populations with limited or no effective treatment options.

Solid Tumors